Actinium Pharmaceuticals Inc (ATNM) Total Debt to Capital

Actinium Pharmaceuticals, Inc. - graphic logo of issuer ATNM

Actinium Pharmaceuticals (ATNM) bases its operations on New York-based radiopharmaceutical centers, while isotope synthesis is entrusted to specialized nuclear laboratories with enhanced security. This chart of the share price demonstrates the 0.04 metric. The business relies on external contractors for clinical trials, manufacturing, and global logistics to maintain a maximum focus on discovering blood cancer therapies.

actiniumpharma.com (ATNM): Debt to Equity Ratio from 07/04/2022 to 11/01/2026

Metric breakdowns and analytics for Actinium Corp (ATNM)

- share price and consensus valuation forecast:
Stock Price Actinium Pharmaceuticals, Inc.|ATNM - Consensus Target
- market capitalization details:
Market Capitalization Actinium Pharmaceuticals|ATNM - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Actinium Pharmaceuticals|ATNM - Accounting Capitalization|Market Capitalization to Book Value Ratio actiniumpharma.com|ATNM - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Actinium Pharmaceuticals|ATNM - Long-Term Liabilities to Capital|Short-Term Debt to Equity Actinium Pharmaceuticals|ATNM - Aggregate Debt Obligations|Debt to Book Value Actinium Pharmaceuticals|ATNM - Company Long-Term Loans and Borrowings|Company Short-Term Debts Actinium Pharmaceuticals|Quick Liquidity actiniumpharma.com
- net income and valuation ratios data:
ATNM - Company Net Income
Fundamental company valuation:Actinium Pharmaceuticals, Inc.
Finished products of Actinium Pharmaceuticals

Developing a targeted radiotherapy ecosystem for hematology requires significant investment, making financial leverage control critically important. By analyzing the debt-to-equity ratio, an investor assesses the proportion of borrowed capital within the balance sheet structure, where a decrease in this metric confirms the high autonomy and stability of Actinium Pharmaceuticals (ATNM) market value in the face of debt risks.

Competitor analysis for Actinium Pharmaceuticals

TGTX (TG Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Arcellx Inc (ACLX)|Total Debt to Capital IRON|Total Debt to Capital Syndax Corp (SNDX)|Debt to Equity Kura Oncology, Inc. KURA|ADCT: Debt to Equity Ratio|Foghorn - Total Debt to Capital|Vor Biopharma, Inc. (VOR) - Total Debt to Equity Ratio|NKTX: Total Debt to Capital|Debt to Capital Coeptis Therapeutics, Inc. (COEP)|Debt to Equity Estrella Immunopharma|CASI: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Debt to Equity|APTO - Debt to Equity|BPTH: Debt to Equity|MEI Pharma (MEIP) - Debt to Equity|Debt to Capital Vincerx Pharma (VINC)